RespiGam

RespiGam

Neonatology An IV immune globulin used to protect against RSV in high-risk children ≤ age 2 with bronchopulmonary dysplasia or prematurity. See Respiratory syncytial virus.
References in periodicals archive ?
RespiGam was approved in 1996, then supplanted with palivizumab, as a medication to reduce the burden of respiratory syncytial virus disease.
Respiratuvar sinsisyal virusun etkili tedavisinin ve asisinin olmamasi nedeniyle, RSV enfeksiyonlarindan korunmak icin riskli hasta grubuna RSV IVIG (Respigam) ve RSV monoklonal antikorlar (Palivizumab-Synagis) ile koruma onerilmektedir (12,13).
Ga-maglobulin preparations with high concentrations of preventive antibodies (Respigam) or humanized monoclonal RSV specific antibody (Palivizumab; Synagis) may be used prophylactically (11).
133[4]:492-99, 1998), safety was an issue in children with cyanotic congenital heart disease treated with respiratory syncytial virus immune globulin (RespiGam).
RespiGam can reduce the rate of hospitalization by 41% and prevent nasal or upper respiratory infections from becoming lower respiratory illnesses, he said.
But the route of administration, intramuscular injection, is a plus for palivizumab; RespiGam requires a 4- to 6-hour intravenous infusion.
RSV-IGIV (RespiGam, Massachusetts Public Health Biologic Laboratories, and Medimmune, Inc, Gaithersburg, MD) was approved for use by the FDA in 1996 for the prevention of severe RSV infection in those children less than 24 months of age with chronic lung disease or premature birth (35 weeks gestation) (AAP, 1998).
* Comment: Pediatric patients with uncorrected congenital heart disease were intentionally excluded from initial palivizumab studies because more children with the condition died in a study of another RSV treatment, RespiGam (respiratory syncytial virus immune globulin intravenous) (J.
* Comment: Pediatric patients with uncorrected congenital heart disease were intentionally excluded from initial palivizum ab studies because more children with the condition died in a study of another RSV treatment, RespiGam (respiratory syncytial virus immune globulin intravenous) (J.
The vial of RespiGam must be kept refrigerated, but not frozen.
Food and Drug Administration (FDA) has approved the use of respiratory syncytial virus immune globulin (RespiGam [TM]) to prevent RSV infection in infants at high risk of complications from the illness.
RSV immune globulin (RSV-IG) is purified from adult human plasma selected for high titers of RSV-neutralizing antibody (minimum 1:3000, compared with about 1:1000 found in standard IVIG) ("RespiGam," 1996).